Results 161 to 170 of about 2,670,948 (286)

Advanced Hemodynamic Monitoring During Postresuscitation Care After Out-of-Hospital Cardiac Arrest: Protocol for a Scoping Review. [PDF]

Acta Anaesthesiol Scand
Grand J, Lau FF, Hassager C, Bro-Jeppesen J, Møller JE, Jakobsen JC, Taccone FS, Russo JJ, Ameloot K, Skrifvars MB, van Diepen S, Kjærgaard J.   +11 more
europepmc   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Hemodynamic monitoring: basic principles in operation room and intensive care unit. [PDF]

J Clin Monit Comput
Mirus M, Saugel B, Spieth PM.
europepmc   +1 more source

Interventional therapies for chronic heart failure: An overview of recent developments

ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.
Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu   +7 more
wiley   +1 more source

Agreement and trending ability between non-invasive and invasive hemodynamic monitoring during cesarean section under spinal anesthesia: a prospective observational study. [PDF]

Front Med (Lausanne)
Shi Y, Ma Y, Cun J, Yu X, Chen Y.
europepmc   +1 more source

Cardiogenic shock mortality according to Aetiology in a Mediterranean cohort: Results from the Shock‐CAT study

ESC Heart Failure, Volume 12, Issue 2, Page 1336-1345, April 2025.
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García, Teresa López‐Sobrino, Esther Sanz‐Girgas, Maria R. Cueto, Jaime Aboal, Pablo Pastor, Irene Buera, Alessandro Sionis, Rut Andrea, Judit Rodríguez‐López, Jose Carlos Sánchez‐Salado, Carlos Tomas, Jordi Bañeras, Albert Ariza, Josep Lupón, Antoni Bayés‐Genís, Ferran Rueda, Grup de Treball de Cures Agudes Cardiològiques Societat Catalana de Cardiologia   +17 more
wiley   +1 more source

Aligning cardiac monitoring with American Heart Association Guidelines: Impact on utilization, hemodynamic monitoring, and outcomes. [PDF]

PLoS One
Hilliard B, Mehta T, Grace J, Pestka DL, Ingraham NE, Beebe T, Tignanelli C, Melton GB, Shippee N, Koopmeiners JS, Usher M.   +10 more
europepmc   +1 more source

Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet‐induced obesity

ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira, Julia Theisen, Katharina J. Ermer, Marie Oertel, Anton Xu, David Weissman, Katharina Ecker, Jan Dudek, Martin Fassnacht, Alexander Nickel, Michael Kohlhaas, Christoph Maack, Ulrich Dischinger   +12 more
wiley   +1 more source

Beyond Standard Parameters: Precision Hemodynamic Monitoring in Patients on Veno-Arterial ECMO. [PDF]

J Pers Med
Torre DE, Pirri C.
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source